The clinical and immunologic response to a modified rapid (r) regimen of venom immunotherapy was evaluated and compared to a traditional (t) therapeutic regimen. Nineteen patients in the r group received a starting dose of 0.01 μg and reached a maintenance dose of 50 μg in 7 weeks. Twelve patients in the t group received an average of twenty-one injections on a weekly basis, reaching the same maintenance dose. The age and sex distribution and pre-treatment venom-specific IgE titres (RAST) of both groups were comparable.
There were thirteen local reactions to venom therapy in both groups and no systemic reactions. Following therapy, most patients developed a rising titre of serum venom-specific IgG (V-IgG). Serum venom-specific IgE (V-IgE) changes were similar in the two groups; over half of the patients had a falling titre when on maintenance dose.
Twelve patients were re-stung after reaching maintenance dose. Only one developed a mild systemic reaction, an individual who failed lo show a V-IgG response with rapid therapy. Five of nine patients did not have an anamnestic V-IgE response.
This rapid method of venom immunotherapy appears to be safe, clinically effective, and comparable to traditional dosing without additional adverse reaction.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.